These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22349160)

  • 1. Comparative adherence to oxybutynin or tolterodine among older patients.
    Thompson A
    Eur J Clin Pharmacol; 2012 Jul; 68(7):1119; author reply 1121. PubMed ID: 22349160
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative adherence to oxybutynin or tolterodine among older patients.
    Gomes T; Juurlink DN; Mamdani MM
    Eur J Clin Pharmacol; 2012 Jan; 68(1):97-9. PubMed ID: 21710237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.
    Rovner ES; Wein AJ
    BJU Int; 2000 Oct; 86 Suppl 2():44-53; discussion 53-4. PubMed ID: 11501617
    [No Abstract]   [Full Text] [Related]  

  • 5. What is the success of drug treatment in urge urinary incontinence? What should be measured?
    Dede H; Dolen İ; Dede FS; Sivaslioglu AA
    Arch Gynecol Obstet; 2013 Mar; 287(3):511-8. PubMed ID: 23086134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of serious falls associated with oxybutynin and tolterodine: a population based study.
    Gomes T; Juurlink DN; Ho JM; Schneeweiss S; Mamdani MM
    J Urol; 2011 Oct; 186(4):1340-4. PubMed ID: 21855905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability.
    Kilic N; Balkan E; Akgoz S; Sen N; Dogruyol H
    Int J Urol; 2006 Feb; 13(2):105-8. PubMed ID: 16563131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of reformulation: improved therapeutic index.
    MacDiarmid S; Sandage BW; Malhotra BK
    Curr Urol Rep; 2008 Nov; 9(6):465-71. PubMed ID: 18947511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolterodine causes measurable restoration of urethral sensation in women with urge urinary incontinence.
    Kenton K; Lowenstein L; Brubaker L
    Neurourol Urodyn; 2010 Apr; 29(4):555-7. PubMed ID: 19771598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
    Hughes DA; Dubois D
    Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
    Harvey MA; Baker K; Wells GA
    Am J Obstet Gynecol; 2001 Jul; 185(1):56-61. PubMed ID: 11483904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolterodine for the treatment of urge urinary incontinence.
    Elterman DS; Chughtai B; Kaplan SA; Barkin J
    Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment.
    de Jong TP
    J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695627
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment.
    Jorgensen TM
    J Urol; 2009 Oct; 182(4 Suppl):2038; discussion 2039. PubMed ID: 19695626
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment.
    Yang SS
    J Urol; 2009 Oct; 182(4 Suppl):2038-9; discussion 2039. PubMed ID: 19695625
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
    Malone-Lee J; Shaffu B; Anand C; Powell C
    J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective.
    O'Brien BJ; Goeree R; Bernard L; Rosner A; Williamson T
    Clin Ther; 2001 Dec; 23(12):2038-49. PubMed ID: 11813937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
    Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
    Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.